Cellnovo s'introduit sur Euronext Paris

Raises €31.6 million, market capitalisation €113.6 million

Paris – 10 July 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1], today celebrated the listing of Cellnovo Group (Cellnovo), a medical devices company that has developed and markets the first connected insulin micro-pump for managing diabetes. The company was admitted on the Compartment C of Euronext Paris.

Based in France and the United Kingdom, Cellnovo has developed and markets the first connected all-in-one diabetes management that helps make life easier for diabetics. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time.

Cellnovo aims to improve the quality of life of patients with type 1 diabetes and more generally all insulin dependent people, by using its technology to minimise the constraints and risks associated with this illness.

Cellnovo (ticker code: CLNV) was listed through the admission to trading on 10 July 2015 of the 10.683.873 ordinaryshares making up its equity, including 2.969.557 new shares issued through a Global Offering[2].

The admission and issue price of Cellnovo shares was set at €10.63per share. Market capitalisation was around €113.569.570on the day of listing. The total amount raised was €31.566.391million.

Eric Beard, Chairman and CEO of Cellnovo, said:«We are pleased to welcome new top-quality investors alongside our historical shareholders and Air Liquide Venture Capital. We thank each of them for putting their trust in our disruptive insulin pump technology. Now we look forward to working with them towards bringing the company to a next level, through the scale-up of our production capabilities and the speed-up of our commercial expansion.»

Albert Ganyushin, Head of International Listings , Euronext added: «We are delighted to welcome Cellnovo on Euronext Paris. Cellnovo’s innovative solution combining e-health and a connected micro-pump for diabetes patients provides a glimpse into the future of healthcare. We are delighted that this innovative company, founded in the United Kingdom, turned to our markets to finance the next stage of its growth.
Cellnovo's listing highlights our ability to attract leading European life science companies to our market, the growing international reputation of our franchise and Euronext's continued momentum in the current market conditions.»

_{[1]Small and medium-size companies

[2]The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.}

Press Release Footer

About Euronext
Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway, and Portugal. As of March 2025, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway, and Portugal host nearly 1,800 listed issuers with around €6.3 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices.
For the latest news, follow us on X (x.com/euronext) and LinkedIn (linkedin.com/company/euronext).

_Disclaimer
_{This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at}_{www.euronext.com/terms-use}_.